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Abstract: Prostate cancer is the fifth leading cause of male cancer death worldwide. Although docetaxel
chemotherapy has been used for more than fifteen years to treat metastatic castration resistant prostate
cancer, the high inter-individual variability of treatment efficacy and toxicity is still not well understood.
Since prostate cancer has a high heritability, inherited biomarkers of the genomic signature may be
appropriate tools to guide treatment. In this review, we provide an extensive overview and discuss the
current state of the art of pharmacogenomic biomarkers modulating docetaxel treatment of prostate
cancer. This includes (1) research studies with a focus on germline genomic biomarkers, (2) clinical
trials including a range of genetic signatures, and (3) their implementation in treatment guidelines.
Based on this work, we suggest that one of the most promising approaches to improve clinical
predictive capacity of pharmacogenomic biomarkers in docetaxel treatment of prostate cancer is the
use of compound, multigene pharmacogenomic panels defined by specific clinical outcome measures.
In conclusion, we discuss the challenges of integrating prostate cancer pharmacogenomic biomarkers
into the clinic and the strategies that can be employed to allow a more comprehensive, evidence-based
approach to facilitate their clinical integration. Expanding the integration of pharmacogenetic markers
in prostate cancer treatment procedures will enhance precision medicine and ultimately improve
patient outcomes.
Keywords: castration resistant prostate cancer; docetaxel; pharmacogenomic biomarker;
personalised treatment
1. Introduction
Prostate cancer (PC) remains the second most common cancer in men, and one of the leading
causes of death among Western males [1]. This is due to the fact that treatment of metastatic prostate
cancer (mPC) is becoming increasingly challenging [2,3]. Docetaxel chemotherapy was approved
15 years ago to treat metastatic castration-resistant prostate cancer (mCRPC), and is now standard
care for this stage of disease [2]. Although other drugs have since been developed, some of which
are administered in combination regimens with docetaxel, docetaxel remains the main choice of
chemotherapeutic agent [4].
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Significant progress has been made in genetic biomarker-based treatment of several cancer
types [5,6]; however, personalized treatment of PC is lagging behind. Also, it is increasingly
evident that the wide variability in treatment response, toxicity, and disease progression between PC
patients is due to the genetic heterogeneity of the disease. Therefore, underlying genetic variations
are potentially eligible biomarkers for targeted therapy, or to predict drug response and adverse
side effects [7]. Treatment-associated, germline genomic biomarkers have several advantages:
they are static, can be easily determined, and are robust predictors of drug response/resistance
and toxicity. Biomarkers, including somatic genomic alterations, structural variants (e.g., gene fusions,
gene rearrangements), splice variants, miRNAs, and differential gene expression, and methylation
markers have also been shown to modulate docetaxel treatment of PC [8].
The focus of this review is to discuss the current state-of-the-art pharmacogenomic biomarkers
modulating docetaxel treatment of PC. The review includes research studies focusing on germline
genomic biomarkers, clinical trials designed to incorporate all type of biomarkers, and finally,
the implementation of biomarkers in treatment guidelines.
2. Docetaxel in Prostate Cancer Treatment
Docetaxel is a taxane, a chemotherapeutic agent that produces antitumour activity. It has
been previously approved for the treatment of breast cancer and non-small-cell lung cancer,
and was approved by the United States Food and Drug Administration on May 19, 2004 for use
in combination with prednisone for the treatment of metastatic, androgen-independent prostate
cancer (AIPC)/hormone-refractory prostate cancer (HRPC) [9,10]. Docetaxel is a semi-synthetic,
second-generation taxane derived from a compound found in the European yew tree (Taxus baccata).
Docetaxel displays potent and broad antineoplastic properties. It binds to and stabilizes tubulin,
thereby inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and
cell death. This agent also inhibits pro-angiogenic factors, such as vascular endothelial growth factor
(VEGF), and displays immunomodulatory and pro-inflammatory properties by inducing various
mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing
agent as well [11].
The pharmacodynamics and pharmacokinetics of docetaxel are extremely complex and have been
the subject of intensive investigation. Docetaxel is metabolized both by CYP3A4 and CYP3A5 [12].
Docetaxel is the substrate for the ATP-binding, cassette multidrug transporters ABCB1, ABCG2,
ABCC1 and ABCC2. However, SLCO1B3 was identified as the most efficient influx transporter for
docetaxel [13].
Unfortunately, most patients develop resistance to docetaxel. Mechanisms of resistance to
chemotherapy include tubulin alterations, increased expression of multidrug resistance genes,
TMPRSS2–ERG fusion genes, kinesins, cytokines, components of other signaling pathways,
and epithelial–mesenchymal transition [14].
It is important to note that docetaxel has no PC treatment-guiding pharmacogenomic biomarker
included on the drug label, based on the information available from the U.S. Food and Drug
Administration (FDA) [15] and the European Medicines Agency (EMA) [16].
3. Germline Genomic Biomarkers in Research Studies for Prostate Cancer Treatment
with Docetaxel
Clinical research studies have investigated the genomic biomarkers of docetaxel monotherapy;
however, combination therapies with distinct mechanisms of action represent a more effective strategy.
Combination therapies are thought to exert cancer-killing functions through either concomitant targeting
of multiple pro-cancer factors or more effective inhibition of a single pathway [17]. The exact mechanisms
by which these combinations can overcome drug resistance have yet to be fully understood [17].
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Studies of germline genomic biomarkers affecting individual differences in docetaxel monotherapy
(I) and combination treatment (II) of PC published between 2006 and 2018 are summarized in
chronological order in Table 1.
3.1. Docetaxel Monotherapy
Tran et al. [18] studied the pharmacokinetics of docetaxel and concluded that CYP3A4
(rs2740574) and CYP3A5 (rs776746) polymorphisms are associated with enhanced docetaxel
clearance. Therefore, patients carrying the CYP3A4*1B allele may be underexposed to the treatment.
Furthermore, GSTP1*A/*B (rs1695) and MDR1 3435TT (rs1045642) carriers are linked to excessive
hematologic febrile neutropenia toxicity [18]. A second study has also suggested that variants in ABCC2
(rs12762549) and SLCO1B3 (rs11045585) may predict the risk of leukopenia/neutropenia induced by
docetaxel chemotherapy [19]. However, in a study of 64 U.S. cancer patients who received a single
cycle of 75 mg/m2 of docetaxel monotherapy, the ABCC2 variant rs12762549 showed a trend towards
reduced docetaxel clearance, but no association with neutropenia was observed [20].
A case report of a 55-year-old male treated with docetaxel after a radical prostatectomy has
suggested that the CYP1B1 gene may play a role in modulating docetaxel activity [21]. The rs1056836
and rs1800440 CYP1B1 missense variants were linked to better overall survival (OS) of the patient,
who remained disease free until publication of the article (two years). The CYP1B1 isoforms of Leu432
and Ser453 are characterized by inferior catalytic activity, and while docetaxel is not metabolized by
CYP1B1, its low activity may favorably influence docetaxel sensitivity by impaired estrogen metabolite
production, which in turn could interfere with binding of the drug to tubulin [21].
Sobek and colleagues studied variants of the ABCG2 transporter protein, which eﬄuxes folate,
dihydrotestosterone, and chemotherapeutic drugs, among other molecules, out of cells [22]. In in vitro
experiments using HEK293 cells (as exogenous ABCG2 expression in PC cell lines led to selective
disadvantage), the rs2231142 (Q141K) variant was observed to eﬄux less folate. This variant makes the
cells more sensitive to docetaxel treatment compared to the wild-type ABCG2. Based on these findings,
the authors conclude that the Q141K variant predisposes the cells to less efficient docetaxel eﬄux,
leading to increased intracellular docetaxel levels and thus increased docetaxel sensitivity. The effect of
decreased folate eﬄux was also observed in PC patients carrying the Q141K variant; serum folate levels
were significantly lower compared to patients carrying wild-type ABCG2. The authors suggested
that increased intra-tumoral folate levels enhance cancer cell proliferation, which may explain why
patients with the Q141K variant had a significantly shorter time to prostate-specific antigen (PSA)
recurrence after a prostatectomy. The authors concluded that PC patients with the Q141K variant may
have a better response to docetaxel, and they may respond differently to treatments that aim to inhibit
the eﬄux of chemotherapeutic agents [22].
3.2. Docetaxel Combination Therapies
3.2.1. Docetaxel and Vinorelbine or Estramustine Phosphate
The first investigation of combination therapies was done in 2006. Here, the role of the ABCG2
variant rs2231142 (421C>A; Q141K) in treatment response has been studied in HRPC patients treated
with docetaxel and vinorelbine/estamustine phosphate [23]. There was a significant association
between survival beyond 15 months and the ABCG2 rs2231142 polymorphism. The increased survival
seen in individuals with an ABCG2 rs2231142 polymorphism may suggest a less functional drug
eﬄux pump, leading to increased intracellular (intra-tumoral) docetaxel concentration and improved
cytotoxic activity, lower transporter expression, and improved survival. This variant may therefore
be an important predictor of response and survival in HRPC patients treated with docetaxel-based
chemotherapy. The companion pharmacogenetic study assessed germ-line polymorphisms in genes
known to play important roles in chemotherapy drug transport, metabolism, and mechanism of action.
The effect of ABCG2 polymorphisms on docetaxel pharmacokinetics is unknown [23].
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3.2.2. Docetaxel and Estramustin, Thalidomide, and Prednisone
The role of CYP1B1 variation in treatment response has also been investigated in AIPC patients
receiving docetaxel-based combination therapies with estramustin, thalidomide, and prednisone [24].
Individuals carrying two copies of the CYP1B1*3 (rs1056836) variant had a poor prognosis compared
to individuals carrying at least one copy of the CYP1B1*1 ancestral allele. The association between
CYP1B1*3 and response to therapy was not observed in comparable subjects receiving non-taxane-based
therapy. The systemic clearance of docetaxel was also unrelated to CYP1B1 genotype status,
indicating that the association of CYP1B1*3 with clinical response (CR) is not due to docetaxel
metabolism. This pilot study provides evidence that CYP1B1*3 may be an important marker for
estimating docetaxel efficacy in patients with AIPC. This link is likely associated with CYP1B1*3
genotype-dependent estrogen metabolism. Specifically, that CYP1B1-generated estrogen metabolites
may bind to tubulin [25], and potentially could interfere with docetaxel-mediated tubulin stabilization.
In addition, estrogen metabolites may also react with docetaxel and structurally alter the drug [24].
3.2.3. Docetaxel and Thalidomide
Docetaxel therapy in combination with thalidomide has led to several pharmacogenomic findings.
Thalidomide is suggested to play a role in inflammation, immunomodulation, and anti-angiogenesis,
and thus influences disease progression [26]. A study by Sissung et al. investigated the association
of ABCB1 1236C>T (rs1128503), 2677 G>T/A (rs2032582), and 3435 C>T (rs1045642) polymorphisms
and treatment efficacy, measured by survival after treatment or peripherial neuropathy in AIPC
patients treated with docetaxel alone (n = 23) or docetaxel and thalidomide (n = 50) [27]. While the
ABCB1 1236C-2677G-3435C ancestral haplotype was associated with improved OS in docetaxel treated
patients, the ABCB1 2677T-3435T variant haplotype was significantly associated with shorter median
OS in patients treated with both docetaxel and thalidomide. Among both treatment arms together,
individuals carrying the 2677GG ancestral genotype had a significantly longer time to neuropathy.
Finally, there was a strong trend toward patients carrying the 2677TT-3435TT diplotype having higher
grades of neutropenia. Interestingly, none of the variants associated with OS or toxicity had a significant
effect on docetaxel pharmacokinetics [27]. These results suggest that variant alleles associated with
lowered ABCB1 expression and altered function result in a clinical phenotype of reduced docetaxel
efficacy and increased toxicity (TOX) in men with AIPC. It is possible that expression of ABCB1 outside
of the liver is responsible for these findings, as polymorphic ABCB1 variants can modulate the exposure
of ABCB1 substrates in tumor cells where this gene is highly up-regulated. It is also notable that
efficacy is decreased while TOX is increased in patients carrying variant alleles [27].
Additional genetic polymorphisms have been analysed for associations with clinical response
(CR) and TOX in a study of CRPC patients receiving either docetaxel and thalidomide or docetaxel
alone [28]. PPAR-δ variants rs6922548, rs2016520, rs1883322, rs3734254, and rs7769719, as well
as the SULT1C2 variant rs1402467 were all observed to be associated with CR. Several variants
in the CHST3 gene were linked to CR exclusively (rs4148943, rs4148947, rs12418, and rs730720),
while others were liked to both CR and TOX (rs4148950, rs1871450, and rs4148945). Variants in SPG7
(rs2292954, rs12960), CYP2D6 (CYP2D6*19), NAT2 (rs1799931), ABCC6 (rs2238472), ATP7A (rs2227291),
CYP4B1 (rs4646487), and SLC10A2 (rs2301159) were associated exclusively with TOX. These data
revealed that polymorphisms in three genes (PPAR-δ, SULT1C2, and CHST3) were associated with
clinical outcome measure of OS, whereas polymorphisms in eight genes (SPG7, CHST3, CYP2D6,
NAT2, ABCC6, ATP7A, CYP4B1, and SLC10A2) were associated with TOX. Although all of these
genes may be related to drug metabolism directly, and thus could be related to pharmacokinetics,
they also participate in pathways that may affect drug action and could therefore be involved
in pharmacodynamic interactions as well. Differences between the two treatment arms were seen
exclusively in thePPARδ gene, where strong relationships withPPARδ single nucleotide polymorphisms
(SNPs) were observed in only those patients who received both docetaxel and thalidomide, but not
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docetaxel alone. This shows that allelic variation in PPARδ may influence the therapeutic efficacy of
the anti-angiogenesis agent thalidomide [28].
As genetic variability in liver enzymes is often linked to interindividual variation in liver
metabolism, Sissung et al. hypothesised that certain variants and genes in these pathways may
be behind the risk and prognosis of CRPC [29]. Patients treated with docetaxel and thalidomide
and who carried variants in ABCB11 (rs7602171 GA/AA), ABCB4 (rs2302387 CT), ABCC5 (rs939339
AG), and SLC5A6 (rs1395 GA/AA) had poor OS compared to those carrying only wild-type alleles,
whereas the GSTP1 rs1799811 CT genotype was associated with prolonged OS. Of considerable interest
are several associations between CRPC prognosis and protein transporters that regulate bodily sterol
and fatty acid deposition. In this small pilot study, there was suggestive evidence that SNPs in bile
acid and fat catabolism genes may be related to CRPC OS. No evidence was found that any of the
aforementioned SNPs were related to risk of developing CRPC [29].
3.2.4. Docetaxel and Prednisone
CYP1B1 variation has also been studied in relation to its role in modulating docetaxel treatment
response when combined with prednisone [30]. Patients carrying the CYP1B1-432ValVal (rs1056836,
corresponding to 4326GG) genotype experienced a significantly lower response rate, as well as
shorter progression-free survival (PFS) and OS, and its prognostic significance for OS was confirmed.
In contrast, no correlations were observed between both the CYP1B1 C142G (rs10012) or CYP1B1
A4390G (rs1800440) polymorphisms and clinical outcome in CRPC patients treated with docetaxel and
prednisone. In summary, the CYP1B1 4326GG polymorphism was linked to docetaxel CR, and may
represent a potential new marker for treatment optimization [30].
3.2.5. Docetaxel and Estramustine, Thalidomide, and Ketoconazole
To explore the role of variants in the estrogen pathway and treatment response in a clinical trial
setting, CRPC patients treated with docetaxel monotherapy, or different combinations of docetaxel with
estramustine, thalidomide, and ketoconazole were genotyped for polymorphisms in estrogen synthesis
(CYP19 rs700519) and estrogen target (ERα rs2234693, rs9340799) genes [31]. Patients carrying two
copies of ERα polymorphisms had shorter progression-free survival (PFS) on docetaxel than other
patients. When the analysis was limited to non-obese patients, the relationship between the ERα
rs9340799 polymorphism and PFS improved. These results supported the hypothesis that reactive
estrogen species cause genotoxicity, and may interfere with docetaxel-mediated tubulin polymerization,
resulting in shortened survival in men with CRPC. The CYP19 variant was moderately associated
with the duration of survival after docetaxel therapy in patients who were greater than 70 years old.
Both ERα polymorphisms were also associated with an increase in CRPC risk, and the association with
ERα variant rs2234693 also improved in those men who were greater than 70 years old. This study
demonstrates that estrogen-related genetic variation affects docetaxel CR, and that this relationship
is dependent on age and body type in men with CRPC. Moreover, this study suggests that ERα
polymorphisms confer the risk of developing CRPC, especially in men under 70 years of age [31].
3.2.6. Docetaxel, Prednisone, and Metronomic Cyclophosphamide
Since VEGF is thought to play an important role in angiogenesis and tumor proliferation, a study of
theVEGF gene in mCRPC patients treated with a combination of docetaxel, prednisone, and metronomic
cyclophosphamide was done [32]. The authors observed significantly longer PFS in patients carrying
the VEGF rs1570360 AG/GG genotypes. Notably, the AA genotype was associated with reduced VEGF
transcription, suggesting that tumors with the VEGF 21154 AG/GG genetic background may produce
higher VEGF-A levels after the administration of standard chemotherapy. The authors suggest that
VEGF and bFGF plasma levels at the end of the first cycle of chemotherapy and VEGF genotyping
may be used to predict which patients will have greater PFS from this particular combination of
therapies [32].
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3.2.7. Docetaxel and Atrasentan
Finally, the role of variation in the α-1 acid glycoprotein (AAG) gene has been explored in PC
patients receiving combination intravenous docetaxel and oral atrasentan therapy [33]. The results
suggested that the AAG genetic polymorphism, rs250242, may explain some inter-patient variability
in docetaxel pharmacokinetics. An evaluation of the pharmacokinetics of both drugs showed that
the systemic clearance of docetaxel was increased by approximately 21% when given concomitantly
with atrasentan; however, atrasentan pharmacokinetics did not appear to be influenced by docetaxel
administration [33].
3.2.8. Docetaxel and Dexamethasone
A genome-wide association study of docetaxel treatment in combination with dexamethasone
in hormone-refractory PC patients has shown that the rs875858 SNP in VAC14 is significantly
associated with increased neuropathy risk, irrespective of patient randomisation to bevacizumab or
a placebo [34]. While not significant genome-wide, two additional ATP8A2 SNPs, rs11017056 and
rs1326116, showed a trend towards increased neuropathy risk. The authors recommend that VAC14
should be prioritized for further validation to determine its role as a predictor of docetaxel-induced
neuropathy and as a biomarker for treatment individualization.
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Table 1. Research studies of germline biomarkers in docetaxel and combination treatment of prostate cancer.
Biomarker Variant Effect Number of Samples/Study Method Study Type Country Reference
I. Docetaxel Monotherapy
CYP3A4 rs2740574 (c.−392G>A) D (Clearance↑)
58 patients initiating chemotherapy Interventional France Tran et al. [18]
CYP3A5 rs776746(c.219−237A>G) D (Clearance↑)
GSTP1 rs1695 (A313G, Ile105Val) TOX
MDR1 rs1045642 (C3435T,Ile1145Ile) TOX
ABCC2 rs12762549 TOX 84 patients: 28 patients with
leukopenia/neutropenia vs. 56 with no TOX Case–control
Japan Kiyotani et al. [19]
SLCO1B3 rs11045585 TOX
CYP1B1
rs1056836 (C1294G,
Leu432Val) OS
55-year-old male with multifocal
adenocarcinoma; 75 mg/m2 docetaxel every
three weeks for six cycles
Case report Italy Brandi et al. [21]
rs1800440 (A1358G,
Asn453Ser)
ABCC2 rs12762549 D (Clearance↓) 64 patients received a single cycle of
75 mg/m2 docetaxel Interventional United States Lewis et al. [20]SLCO1B3 rs11045585 No effect
ABCG2 rs2231142 (C421A, Q141K) CR HEK293 cells, 40 patients In vitro, Validatedin vivo United States Sobek et al. [22]
II. Docetaxel Combination Therapies
Docetaxel and Vinorelbine, Estramustine Phosphate
ABCG2 rs2231142 (C421A, Q141K) OS
64 chemotherapy-naive patients with HRPC
were randomized to (1) docetaxel (20 mg/m2
i.v. days 1 and 8) + vinorelbine (25 mg/m2 i.v.
days 1 and 8) and (2) docetaxel (60–70 mg/m2
i.v. day 1) + estramustine phosphate (280 mg
oral 3x/day, days 1–5)
Interventional United States Hahn et al. [23]
Docetaxel and Estramustin, Thalidomide, Prednisone
CYP1B1 rs1056836 (C4326G,Leu432Val) OS
52 patients with AIPC: (1) docetaxel (n = 25, 1
h i.v.,30 mg/m2); (2) docetaxel + estramustine
+ thalidomide (n = 20, 30 min i.v., 30 mg/m2)
docetaxel + prednisone (n = 7,
1 h i.v., 75 mg/m2)
Observational
retrospective United States Sissung et al. [24]
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Table 1. Cont.
Biomarker Variant Effect Number of Samples/Study Method Study Type Country Reference
Docetaxel and Thalidomide
ABCB1
rs1128503 (C1236T) OS AIPC patients; 50 patients with docetaxel +
thalidomide; 23 patients with docetaxel; Interventional United States
Sissung et al. [27]rs2032582 (G2677T/A) OS, TOX
rs1045642 (C3435T) OS, TOX
PPAR-δ
rs6922548 CR
74 CRPC patients: (1) CRPC patients (n = 25)
with docetaxel (30 mg/m2 weekly for three
weeks, followed by a one-week rest); (2)
patients (n = 49) with docetaxel (30 mg/m2
weekly for three weeks followed by
a one-week rest) + thalidomide (200 mg orally
each day)
Interventional United States Deeken et al. [28]
rs2016520 CR
rs1883322 CR
rs3734254 CR
rs7769719 CR
CHST3
rs4148943 CR
rs4148947 CR
rs12418 CR
rs730720 CR
rs4148950 CR, TOX
rs1871450 CR, TOX
rs4148945 CR, TOX
SULT1C2 rs1402467 CR
SPG7
rs2292954 TOX
rs12960 TOX
CYP2D6 *19 (2539_2542delAACT) TOX
NAT2 rs1799931 TOX
ABCC6 rs2238472 TOX
ATP7A rs2227291 TOX
CYP4B1 rs4646487 TOX
SLC10A2 rs2301159 TOX
ABCB4 rs2302387 OS 74 CRPC patients: (1) patients (n = 49) with
docetaxel (30 mg/m2 weekly for three weeks
followed by a one-week rest); (2) patients
(n = 25) with docetaxel (same schedule) +
thalidomide (200 mg orally each day)
Observational,
retrospective United States
Sissung et al. [29]
ABCB11 rs7602171 OS
ABCC5 rs939336 OS
GSTP1 rs1799811 OS
SLC5A6 rs1395 OS
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Table 1. Cont.
Biomarker Variant Effect Number of Samples/Study Method Study Type Country Reference
Docetaxel and Prednisone
CYP1B1
rs10012 (C142G, Arg48Gly) No effect 60 CRPC patients: (1) docetaxel (1 h,
75 mg/m2 on day 1) every 21 days, or (2)
docetaxel (30 mg/m2 weekly for five of every
six weeks) + prednisone (10 mg os daily)
Interventional Italy Pastina et al. [30]rs1056836 (C4326G,
Leu432Val) CR, OS, PFS
rs1800440 (A4390G,
Asn453Ser) No effect
Docetaxel and Estramustine, Thalidomide, Ketoconazole
CYP19 (now
CYP19A1) rs700519 (c.C790T, R264C) OS
111 CRPC patients: (1) n = 20 with
estramustine, docetaxel, and thalidomide; (2)
n = 21 with ketoconazole + docetaxel; (3)
n = 50 with docetaxel + thalidomide; (4) n = 24
with docetaxel alone; 289 healthy controls
Observational,
retrospective United States
Sissung et al. [31]
ERα (now ESR1) rs2234693 OS
rs9340799 OS
Docetaxel and Prednisone and Metronomic CTX
VEGF-A
rs699947 (A22578C) PFS
41 mCRPC patients on day 1 received
docetaxel (60 mg/m2 intravenously every
three weeks, up to 12 cycles) + prednisone (10
mg/day, from day 2 continuously) + celecoxib
200 mg orally 2×/day
Interventional Italy Derosa et al. [32]rs1570360 (A21154G) PFS
rs2010963 (C2634G) PFS
rs3025039 (C1936T) PFS
Docetaxel and Atrasentan
AAG rs250242 (A4069G) Clearance↑. No infoabout dosage effect.
21 PC patients; docetaxel (60–75 mg/m2, every
3 weeks, i.v.) + atrasentan (10 mg/day starting
on day 3 of cycle 1, given continuously, oral)
Interventional United States Younis et al. [33]
Docetaxel and Dexamethasone
ATP8A2
rs11017056 TOX
623 mCRPC Caucasian patients randomized
into two arms; drugs were administered to
both arms (arm 1 and arm 2): docetaxel
(75 mg/m2 i.v., 1 h on day 1 of each 21-day
cycle) + dexamethasone (8 mg oral, 12, 3, 1 h
prior to docetaxel i.v.) + prednisone (5 mg
oral 2×/day); (arm 1) adding bevacizumab
(15 mg/kg i.v. on day 1 of each cycle), and (arm
2) adding placebo (i.v. on day 1 of each cycle)
Interventional United States Hertz et al. [34]
rs1326116 TOX
VAC14 rs875858 TOX
SNP: single nucleotide polymorphism; mCRPC: metastatic castration resistant prostate cancer; PC: prostate cancer; HRPC: hormone resistant prostate cancer; AIPC: androgen-independent
prostate cancer; i.v.: intravenous; D: dosing; TOX: toxicity; OS: overall survival; CR : clinical response; PFS: progression free survival; CTX: cyclophosphamide.
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4. Clinical Trials of Docetaxel Treatment in Prostate Cancer Incorporating Genomic Signature
Clinical trials have been identified both from ClinicalTrials.gov [35] and from the European Union
(EU) Clinical Trials Register database [36]. Only trials that included patients with PC, docetaxel as the
administered treatment, and evidence of incorporation of genomic signature analyses were included in
this review.
ClinicalTrials.gov and the EU Clinical Trials Register use different terminology for describing the
status of a trial. On ClinicalTrials.gov, the status can be "completed”, “terminated”, “withdrawn”,
“recruiting”, and “active”, as well as “not recruiting”, “not yet recruiting” or “unknown”. “Terminated”
trials have stopped early, but participants have been recruited and they have received intervention,
whereas “withdrawn” trials have stopped before the recruitment of participants. “Active” and
“not recruiting” trials have recruited participants who are currently receiving intervention or are
going through examinations, whereas “not yet recruiting” trials have not recruited any participants.
Therefore, we collectively refer to the “recruiting”, “active”/”not recruiting”, and “not yet recruiting”
trials as ongoing trials. In the EU Clinical Trials Register, the status of a trial can be “completed”,
“prematurely ended”, or “ongoing”.
4.1. Biomarkers in ClinicalTrials.gov
Overall, 132 trials were found from ClinicalTrials.gov with the search algorithm described above.
After removing duplicate results and irrelevant trials, the number of the remaining and analysed trials
was 24.
Of note, there were fewer “completed” or “terminated” trials (Table 2) than “ongoing” clinical
trials (Table 3) [37], indicating the intense translational interest in this field. The reasons for trial
terminations were withdrawal of funding (NCT00503984) or low participant enrollment (NCT01253642).
Four trials had been withdrawn before recruitment of patients, and two trials had unknown status
(Supplementary Table S1).
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Table 2. Completed or terminated clinical trials for docetaxel treatment of prostate cancer (ClinicalTrials.gov).
National
Clinical Trial
Number
Study Period Status Intervention Genomic Signature Phase Total Numberof Participants Study Type Results
NCT00089609 Apr 2005–Jan2018 Completed
docetaxel +
thalidomide +
prednisone +
bevacizumab
Association of SNPs in
CYP3A4, CYP3A5 (docetaxel),
and CYP2C19 (thalidomide)
with pharmacokinetics
and efficacy
II 73 Interventional
Yes. Association of the
SNPs and efficacy was
not investigated.
NCT01308567 May 2011–May2018 Completed
cabazitaxel +
prednisone or
docetaxel +
prednisone
Pharmacogenomics
of cabazitaxel III 1170 Interventional
Yes. Results of
pharmacogenomic
studies were
not published.
NCT00619996 Mar 2007–Jan2009 Completed
sorafenib +
docetaxel
Gene expression profiling on
blood cells and tumor biopsy II 43 Interventional No.
NCT00503984 May 2007–Jun2015
Terminated
(withdrawal of
funding)
azacitidine +
docetaxel +
growth factor
support
GADD45A methylation and
expression after azacitidine
treatment in patients whose
disease is progressing on
docetaxel treatment
I, II 22 Interventional
Yes. Significant
demethylation of
GADD45A was observed.
Azacitidine may reverse
docetaxel resistance.
NCT01253642 Jul 2010–Sep2017
Terminated (low
enrollment)
phenelzine
sulfate +
docetaxel
Frequency of MAOA
overexpression CRPC tumors
that are progressing on
docetaxel treatment.
HIF-1alpha and MAOA
expression in Circulating
Tumor Cells (CTCs).
II 11 Interventional
Yes. MAOA was
overexpressed in all
examined tumors.
HIF-1alpha and MAOA
expression in CTCs was
not analyzed.
Genes 2019, 10, 599 12 of 23
Table 3. Ongoing clinical trials for docetaxel treatment in prostate cancer (“recruiting”, “active”/”not recruiting”, “not yet recruiting”) (ClinicalTrials.gov).
National Clinical
Trial Number Status Interventions Genomic Signature Phase
Participants
(Estimated) Study Type
NCT02975934 Recruiting
rucaparib or abiraterone +
prednisone/enzalutamide/docetaxel
+ prednisone
Response in patients with evidence
of a homologous recombination gene
deficiency (BRCA1/2 or ATM)
III 400 Interventional
NCT03442556 Recruiting docetaxel + carboplatin +rucaparib
Response in patients with
homologous recombination DNA
repair deficiency (BRCA1/2, ATM,
PALB2 germline mutations)
II 20 Interventional
NCT02985021 Recruiting docetaxel + carboplatin
Response in patients with germline
or somatic inactivation of DNA
repair pathway genes (BRCA1,
BRCA2, ATM)
II 35 Interventional
NCT03517969 Recruiting
docetaxel + carboplatin or
carboplatin + ATR1 kinase
inhibitor VX-970
Response in tumors with
homologous recombination
deficiency
II 130 Interventional
NCT02598895 Recruiting docetaxel + carboplatin
Response in tumors with mutation
of DNA repair pathway genes
(BRCA1, BRCA2, ATM)
NA 14 Interventional
NCT03070886 Recruiting
ADT2 + external beam
radiotherapy + docetaxel or ADT +
external beam radiotherapy
Response in genomically defined
sub-groups of patients II, III 612 Interventional
NCT02649855 Recruiting docetaxel + PROSTVAC (vaccine) Evaluate drug metabolism andtransporters II 74 Interventional
NCT03358563 Recruiting ADT + docetaxel + Radicalprostatectomy
Evaluation of genomic signatures
and gene expression after treatment.
Evaluation of biomarkers in tumor
cells in circulation, as well a bone
marrow before and after treatment.
Early I 30 Interventional
NCT03218826 Recruiting docetaxel + AZD8186
Dose escalation and anti-tumor
activity of AZD8186 when given
together with docetaxel in patients’
solid tumors with PTEN or PIK3CB
mutations. Evaluation of co-mutated
genes and their association with
treatment response or resistance.
I 58 Interventional
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Table 3. Cont.
National Clinical
Trial Number Status Interventions Genomic Signature Phase
Participants
(Estimated) Study Type
NCT02362620 Active, not recruiting docetaxel or cabazitaxel
Exploration of prognostic
biomarkers (overall survival).
Evaluation of the prognostic value of
TMPRSS2-ERG re-arrengement,
PTEN loss, and AR splicing variants.
Association of somatic and germline
mutations and the outcomes of
the patients.
NA 402 Observational(prospective)
NCT03700099 Not yet recruiting docetaxel + enzalutamide Association of the AR gene alteration,AR-V7 status, and PSA response. II 30 Interventional
NCT03356444 Not yet recruiting abiraterone + prednisone ordocetaxel + prednisone
Exploration of some of the genes
related to the treatment efficacy II 140 Interventional
NCT03816904 Not yet recruiting docetaxel or paclitaxel
Determination of the number of
CAG triplets in the KCNN3/SK3 gene
associated with neuropathy
NA 250 Observational(prospective)
1 ATR, ataxia telangiectasia and rad3-related; 2 ADT, androgen deprivation therapy.
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The majority of trials were interventional, with only two being observational. In the group of
interventional trials, the phase of the study was defined for 15 trials, most of which were in phase II [38]
(Tables 2 and 3). In the majority of interventional trials, docetaxel was explored in different settings
of combination treatments. In the observational studies, docetaxel was compared to cabazitaxel and
paclitaxel (Table 3), novel antineoplastic agents that interfere with microtubule function, leading to
altered mitosis and cellular death [39].
The genomic biomarkers evaluated in the trials were not always precisely defined, indicating only
that the target of the investigation was a gene expression profile or genes related to treatment
efficacy, but not specifying further. Furthermore, the genetic analyses were inexact in many cases.
Here, we summarize the “completed” or “terminated” clinical trials with output measures and the
“ongoing” trials with possible future results, with special focus on the trials where the genomic profiling
is specified.
Results have been published on two “completed” and two “terminated” trials (Table 2).
However, the results of the completed trials did not include genomic results. In one of these
trials (NCT00089609), the intervention treatment included docetaxel, prednisone, thalidomide,
and bevacizumab, and the studied genes were CYP3A4 and CYP3A5 for docetaxel metabolism
and CYP2C19 for thalidomide metabolism. The exact genetic variants studied and their association
with efficacy were not described in the results. The other “completed” trial (NCT01308567) with results
aimed to investigate the pharmacogenomics of cabazitaxel, but not docetaxel; however, docetaxel was
included in the intervention.
The genetic results of the two “terminated” trials seem to be more impactful. The aim of one
of these, NCT00503984, was to determine whether azacitidine could reverse docetaxel resistance in
mCRPC patients by decreasing methylation of the proapoptotic GADD45A gene [40]. The authors
had previously observed that methylation of GADD45A in DU145 PC cells increases during docetaxel
treatment and contributes to docetaxel resistance [41]. In addition, they found that azacitidine
treatment decreases the methylation of GADD45A and restores docetaxel sensitivity in resistant PC
cells. In the clinical trial, changes in GADD45A methylation were examined in buffy-coat DNA of
patients. After azacitidine treatment, methylation significantly decreased in ten patients, increased in
four patients, and in one patient could not be assessed due to a lacking sample (Phase I, 15 patients).
Six of the ten patients with decreased methylation also had a concomitant decrease in the PSA level,
while none of the four patients with increased methylation had a PSA response. However, the difference
was not statistically significant (p = 0.085). The authors concluded that the addition of azacytidine could
be beneficial in mCRPC patients after initial docetaxel treatment failure [40]. With regards to the second
“terminated” trial (NCT01253642), only the frequency ofMAOA (monoamine oxidase A) overexpression
in tumors that have progressed during docetaxel treatment was reported. MAOA overexpression was
observed in all investigated progressing tumors.
The focus of several ongoing clinical trials (Table 3) is treatment response to docetaxel treatment in
combination with emerging new medications in tumors harbouring inactive mutations in homologous
recombination (HR) genes, including BRCA1, BRCA2, and ATM. Five recruiting trials plan to study the
effect of these genes on treatment response, where treatments including a poly-ADP ribose polymerase
(PARP) inhibitor (rucaparib), a nonsteroidal antiandrogen (enzalutamide), or a chemotherapy drug
(carboplatin), combined with or compared to docetaxel.
A promising recruiting trial, NCT03218826, plans to evaluate the effect of docetaxel combined
with AZD8186, a novel potent small molecule, which targets the lipid kinase PI3Kβ signaling and
inhibits the growth of PTEN-deficient prostate tumors [42].
The effect of androgen receptor (AR) gene alterations and splice variants on treatment response are
going to be evaluated in two trials. The impact of these alterations on PSA response will be evaluated
in docetaxel treatment combined with enzalutamide (NCT03700099), and on patient prognosis related
to docetaxel versus cabazitaxel treatment (NCT02362620), in addition to the effect of TMPRSS2-ERG
rearrangement and PTEN loss.
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Only one trial (NCT03816904) plans to focus on the adverse effects of docetaxel. The aim of
this trial is to investigate the association between the number of CAG triplets in the KCNN3 gene
(which codes for the SK3 calcium channel) and taxane neuropathy in patients who are receiving either
docetaxel or paclitaxel. This trial is a prospective observational trial, and plans to follow patients with
different types of cancer, including PC patients.
4.2. Biomarkers in the EU Clinical Trials Register
In addition to the ClinicalTrials.gov database, clinical trials for docetaxel chemotherapy with
pharmacogenetic aspects were searched for in the EU Clinical Trials Register [36]. A total of 76 trials
were found, and after removing duplicate and irrelevant search results, only four trials remained.
Of the four trials, one was “completed”, one was “terminated”, and two were “ongoing” (Table 4).
Results have been published for the completed and the terminated trials, but no pharmacogenetic
aspects were presented, and only one trial (EudraCT 2006-004478-29) specified which genes (CYP2B6,
CYP2C19, CYP2C9, and CYP3A5) they planned to investigate. In two of the trials, descriptions of
the genetic biomarker investigations were included in a sub-study (EudraCT 2013-000809-23) or in
a separate study planned to be conducted later based on samples collected during the actual trial
(EudraCT 2008-000701-11); however, the specific biomarkers to be studied were not provided.
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Table 4. Clinical trials for docetaxel treatment in prostate cancer in EU Clinical Trials Register.
Eudra Clinical Trial
Number Intervention Genomic Signature Results Phase/Status Study Type/Participants
Comparison with
ClinicalTrials.gov
2008-000701-11
dasatinib + docetaxel +
prednisone OR placebo +
docetaxel + prednisone
Samples collected for future
pharmacogenomic studies
Yes. Nothing on
pharmacogenomics III/Completed Interventional/1930
Listed on ClinicalTrials.gov
Pharmacogenomic aspect was not
mentioned on ClinicalTrials.gov
(NCT00744497).
2007-000323-17
docetaxel + ADT
(leuprolide + bicalutamide)
OR ADT alone
Evaluation of gene expression
profiles, genetic changes,
and quantitative methylation of
different genes, and their ability to
predict the treatment outcome of
high-risk prostate cancer subjects
Yes. Nothing on
pharmacogenomics III/Terminated Interventional/413
Trial was listed on ClinicalTrials.gov.
Pharmacogenomic aspect was
mentioned in the original but not in
the current secondary outcome
measures on ClinicalTrials.gov
(NCT00514917).
2013-000809-23
masitinib + docetaxel +
prednisone OR placebo +
docetaxel + prednisone
In a sub-study: relationship between
genomic data and overall survival No III/Ongoing Interventional/581
Trial was listed on ClinicalTrials.gov
Pharmacogenomic aspect was not
mentioned on ClinicalTrials.gov
(NCT03761225).
2006-004478-29
docetaxel + prednisone +
ciclophosphamide +
celecoxib
Evaluation of the most frequent
genetic polymorphisms of CYP2B6,
CYP2C19, CYP2C9, and CYP3A5
and their association with the
observed response
No II/Ongoing Interventional/45 Not found on ClinicalTrials.gov
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Interestingly, three of the four trials were found retrospectively on ClinicalTrials.gov, but none of
them was found with the search algorithm used there. The reason for this is that the pharmacogenomic
aspects were not mentioned on ClinicalTrials.gov, but they were included to the EU register, albeit briefly.
Notably, in one of these trials the original secondary outcome measures on ClinicalTrials.gov included
the evaluation of genetic biomarkers, but this outcome measure had later been deleted from the trial
description. This change had not been updated in the EU Clinical Trials Register.
5. Pharmacogenomic Biomarkers in Prostate Cancer Treatment Guidelines
The European Association of Urology (EAU) [43,44] and European Society for Medical Oncology
(ESMO) [45] PC treatment guidelines were reviewed for any recommendations on pharmacogenetic
testing before or during docetaxel treatment. In general, the ESMO guideline states that there are no
predictive biomarkers to guide treatment decisions, even though there are some known prognostic
biomarkers. On the other hand, the EAU guideline discusses multiple diagnostic or prognostic genetic
biomarkers and their use in the clinic. These guidelines suggest that the first future application
of pre-emptive genetic testing commence and involve homologous recombination deficiency genes,
since these patients might benefit from treatment with PARP inhibitors [43]. However, no definite
recommendation has been made.
6. Biomarkers with Translational Potential in Docetaxel Treatment of Prostate Cancer
Predictive pharmacogenomic biomarkers of the highest importance, with clinical implementational
potential, are the ones affecting clinical response. Based on research studies on germline genomic
biomarkers, we can conclude that variants in CYP1B1, ABCG2, CHST3, PPAR-δ, and SULT1C2
genes have a documented impact on better clinical response to docetaxel treatment in PC (Table 5).
Pre-emptive genotyping of pharmacogenomic biomarkers affecting docetaxel clearance would be of
especially great value for evidence-based dose decisions. Specifically, CYP3A4, CYP3A5, AAG gene
variants are known to enhance, while the ABCC2 variant is reported to reduce docetaxel clearance in
PC treatment. This may cause an elevated or reduced docetaxel dose, respectively. Docetaxel toxicity
in PC treatment may be avoided by testing for polymorphisms of the following biomarker genes:
CHST3, MDR1/ABCB1, ABCC2, ABCC6, ATP7A, ATP8A2, CYP2D6, CYP4B1, GSTP1, NAT2, SLC10A2,
SLCO1B3, SPG7, and VAC14.
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Table 5. Germline genomic biomarkers in docetaxel treatment of prostate cancer with clinical translational potential.
Biomarker
Predicitive Prognostic
Clinical Response (↑) Toxicity Dosing (Clearance) Overall Survival (↑) Progression FreeSurvival (↑)
CYP1B1 (rs1056836) X XXX X
ABCG2 (rs2231142) X X
CHST3 (rs4148950) X X
CHST3 (rs1871450) X X
CHST3 (rs4148945) X X
MDR1/ABCB1 (rs1045642) XX X
MDR1/ABCB1 (rs2032582) X X
ABCC2 (rs12762549) X X (reduced)
CHST3 (rs4148947) X
CHST3 (rs12418) X
CHST3 (rs730720) X
CHST3 (rs4148943) X
PPAR-δ (rs6922548) X
PPAR-δ (rs2016520) X
PPAR-δ (rs1883322) X
PPAR-δ (rs3734254) X
PPAR-δ (rs7769719) X
SULT1C2 (rs1402467) X
ABCC6 (rs2238472) X
ATP7A (rs2227291) X
ATP8A2 (rs11017056) X
ATP8A2 (rs1326116) X
CYP2D6*19 X
CYP4B1 (rs4646487) X
GSTP1 (rs1695) X
NAT2 (rs1799931) X
SLC10A2 (rs2301159) X
SLCO1B3 (rs11045585) X
SPG7 (rs2292954) X
SPG7 (rs12960) X
VAC14 (rs875858) X
AAG (rs250242) (enhanced)
CYP3A4 (rs2740574) X (enhanced)
CYP3A5 (rs776746) X (enhanced)
ABCB4 (rs2302387) X
ABCB11 (rs7602171) X
ABCC5 (rs939336) X
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Table 5. Cont.
Biomarker
Predicitive Prognostic
Clinical Response (↑) Toxicity Dosing (Clearance) Overall Survival (↑) Progression FreeSurvival (↑)
CYP1B1 (rs1800440) X
CYP19A1 (rs700519) X
ERα/ESR1 (rs2234693) X
ERα/ESR1 (rs9340799) X
GSTP1 (rs1799811) X
MDR1/ABCB1 (rs1128503) X
SLC5A6 (rs1395) X
VEGF-A (rs699947) X
VEGF-A (rs1570360) X
VEGF-A (rs2010963) X
VEGF-A (rs3025039) X
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Prognostic biomarkers have a high importance from clinical and patient perspective. Better overall
survival is influenced by CYP1B1, ABCG2, MDR1, ABCB4, ABCB11, ABCC5, CYP19A1, ERα/ESR1,
GSTP1 and SLC5A6 genes. Importantly, favorable progression-free survival is related to CYP1B1 and
VEGF-A polymorphisms.
In summary, the most important germline pharmacogenetic biomarker originating from the
research studies is CYP1B1 rs1056836, indicating both clinical response, overall and progression-free
survival. In addition, on the same way ABCG2 rs2231142 indicates a better clinical response and
overall survival. CHST3 variants (rs4148950, rs1871450, rs4148945) indicate better clinical response
and toxicity. MDR1/ABCB1 (rs1045642, rs2032582) variants play an important role in better overall
survival and toxicity, while the ABCC2 rs12762549 variant in reduced clearance/dosing and toxicity.
Only one single clinical trial gives a hint on the use of an azacytidine demethylating agent,
which can be beneficial in mCRPC patients who have increased GADD45A gene methylation after
initial docetaxel treatment failure.
Although genetic testing is not recommended yet, these prognostic and predictive germline
genomic biomarkers may have the best translational value.
7. Challenges, Conclusions, and Outlook
The results of the research summarized above justify the increasing number of studies aimed at
identifying the associations between the genetic signatures of PC patients and docetaxel drug response,
resistance, and toxicity.
However, only a minority of the significant pharmacogenetic candidates have been taken forward
for clinical validation. To overcome the challenge of moving biomarkers into a clinical setting,
prospective study designs, larger discovery cohorts, and subsequent clinical validation in good quality
randomized trials are urgently needed.
Another challenge is how to define the best approach for biomarker selection, with enough
evidence to transition them to the clinic. The hurdles include the inherent low frequency of many of
these markers, the lengthy validation process through trials, and legislative and economic issues.
The predictive capacity of pharmacogenomic biomarkers for specific clinical outcome measures
can be improved via composing expanded multigene pharmacogenomic panels defined by drug efficacy,
drug toxicity, clinical response, or survival. Integrating these clinical effect-based pharmacogenomic
panels into future research studies and clinical trials would allow a more comprehensive, evidence-based
approach to determine the significance and importance of genetic testing. Furthermore, with appropriate
consent and pretesting education [46], incorporating biomarker assessment provides the opportunity to
not only assess cancer risk, but facilitate clinical trial eligibility and treatment selection [47]. In addition,
the use of germline genomic biomarkers in cancer treatment is considered to be a less invasive approach
compared to biopsy-originated somatic biomarkers.
Technological requirements for the clinical implementation of biomarker assessment are now
readily available. However, it is important to ensure that continued pharmacogenetic education is
provided to clinical oncologists, and that the benefit of using genetic polymorphisms as predictive
biomarkers in routine and clinical research is stressed.
In summary, considerable progress has been made in the discovery of clinically applicable
pharmacogenomic signatures of docetaxel treatment in PC. However, a more collaborative approach
between stakeholders and studies with specific clinical output measures are needed to pave the way
towards the routine use of pharmacogenomic biomarkers in personalised treatment of PC.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/8/599/s1, Table S1:
Withdrawn trials and trials with unknown status for docetaxel treatment in prostate cancer (ClinicalTrials.gov).
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